Free Trial

iTeos Therapeutics (NASDAQ:ITOS) Earns Outperform Rating from Wedbush

iTeos Therapeutics logo with Medical background

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report)'s stock had its "outperform" rating reiterated by research analysts at Wedbush in a research note issued on Monday,RTT News reports. They currently have a $10.50 price objective on the stock, down from their previous price objective of $12.00. Wedbush's price objective suggests a potential upside of 3.70% from the company's current price.

A number of other analysts also recently commented on the company. JPMorgan Chase & Co. downgraded iTeos Therapeutics from an "overweight" rating to a "neutral" rating and dropped their price objective for the stock from $15.00 to $8.00 in a report on Tuesday, May 13th. Wells Fargo & Company restated an "equal weight" rating and set a $12.00 price objective (down from $13.00) on shares of iTeos Therapeutics in a report on Wednesday, May 28th. Piper Sandler restated an "overweight" rating and set a $12.00 price objective (down from $16.00) on shares of iTeos Therapeutics in a report on Wednesday, May 14th. Leerink Partnrs cut shares of iTeos Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, May 14th. Finally, Raymond James Financial set a $12.00 price target on shares of iTeos Therapeutics in a research report on Wednesday, May 14th. Six research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. According to MarketBeat, iTeos Therapeutics presently has a consensus rating of "Hold" and a consensus price target of $15.64.

Get Our Latest Report on ITOS

iTeos Therapeutics Price Performance

ITOS traded up $0.01 during trading on Monday, hitting $10.13. The company's stock had a trading volume of 745,635 shares, compared to its average volume of 765,140. The firm's 50 day moving average price is $9.63 and its 200-day moving average price is $7.93. The stock has a market cap of $387.48 million, a PE ratio of -3.33 and a beta of 1.49. iTeos Therapeutics has a twelve month low of $4.80 and a twelve month high of $18.13.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last released its quarterly earnings data on Monday, April 28th. The company reported ($0.80) EPS for the quarter, topping analysts' consensus estimates of ($0.94) by $0.14. Equities analysts anticipate that iTeos Therapeutics will post -3.49 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Michel Detheux sold 43,883 shares of the firm's stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $10.02, for a total value of $439,707.66. Following the completion of the transaction, the chief executive officer owned 153,903 shares of the company's stock, valued at approximately $1,542,108.06. This trade represents a 22.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director David Hallal sold 38,228 shares of the stock in a transaction that occurred on Friday, June 6th. The stock was sold at an average price of $10.24, for a total transaction of $391,454.72. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,939,307 shares of company stock worth $16,202,116. Corporate insiders own 12.50% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Wells Fargo & Company MN grew its stake in iTeos Therapeutics by 16.9% in the 4th quarter. Wells Fargo & Company MN now owns 16,644 shares of the company's stock valued at $128,000 after buying an additional 2,402 shares during the last quarter. Virtus ETF Advisers LLC grew its stake in iTeos Therapeutics by 58.2% in the 4th quarter. Virtus ETF Advisers LLC now owns 8,948 shares of the company's stock valued at $69,000 after buying an additional 3,293 shares during the last quarter. Bridgeway Capital Management LLC grew its stake in iTeos Therapeutics by 5.0% in the 4th quarter. Bridgeway Capital Management LLC now owns 69,072 shares of the company's stock valued at $530,000 after buying an additional 3,305 shares during the last quarter. Exchange Traded Concepts LLC grew its stake in iTeos Therapeutics by 25.1% in the 1st quarter. Exchange Traded Concepts LLC now owns 17,308 shares of the company's stock valued at $103,000 after buying an additional 3,468 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in iTeos Therapeutics by 0.7% in the 4th quarter. Geode Capital Management LLC now owns 644,901 shares of the company's stock valued at $4,954,000 after buying an additional 4,551 shares during the last quarter. Institutional investors own 97.16% of the company's stock.

iTeos Therapeutics Company Profile

(Get Free Report)

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

Featured Articles

Analyst Recommendations for iTeos Therapeutics (NASDAQ:ITOS)

Should You Invest $1,000 in iTeos Therapeutics Right Now?

Before you consider iTeos Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iTeos Therapeutics wasn't on the list.

While iTeos Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore
AI Stocks Are Printing Money — These 3 Are Just Getting Started
Why Drone Stocks Are Skyrocketing Right Now!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines